Ivarmacitinib is associated with rapid clinical improvement and immune remodeling in palmoplantar pustulosis: A multicenter, single-arm clinical trial.
J Am Acad DermatolJun 25, 2026 (epub)
Clinical ResearchDermatology
Zhongrui Xu, Wenyao Chen, Jingyu Du et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, single-arm clinical trial evaluated the efficacy and safety of ivarmacitinib in 60 patients with palmoplantar pustulosis (PPP) over 12 weeks. The mean PPPASI score significantly decreased from 11.3 to 3.9 (P < .001), with 85.0% of patients achieving PPPASI50. The study also explored immune remodeling and predictors of response.
Key findings
- Mean PPPASI decreased from 11.3 to 3.9 (P < .001) after 12 weeks.
- 85.0% of patients achieved PPPASI50 and 13.3% achieved PPPASI75.
- Improvements in pruritus, pain, and quality of life were noted by week 2 (all P < .05).
- Twenty-two grade 1-2 adverse events were reported, with 2 patients discontinuing treatment.
Why it matters
The findings suggest that ivarmacitinib may provide a rapid and effective treatment option for patients with palmoplantar pustulosis, a condition with limited therapeutic options. Understanding immune profiles could enhance patient selection for targeted therapies.